- Home
- ATOS vs BWG Comparison
ATOS vs BWG Comparison
Compare ATOS & BWG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- BWG
- Stock Information
- Founded
- ATOS 2009
- BWG 2012
- Country
- ATOS United States
- BWG United States
- Employees
- ATOS N/A
- BWG N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- BWG Finance/Investors Services
- Sector
- ATOS Health Care
- BWG Finance
- Exchange
- ATOS Nasdaq
- BWG Nasdaq
- Market Cap
- ATOS 174.8M
- BWG 148.2M
- IPO Year
- ATOS 2012
- BWG N/A
- Fundamental
- Price
- ATOS $1.47
- BWG $8.80
- Analyst Decision
- ATOS Strong Buy
- BWG
- Analyst Count
- ATOS 3
- BWG 0
- Target Price
- ATOS $6.25
- BWG N/A
- AVG Volume (30 Days)
- ATOS 575.2K
- BWG 53.8K
- Earning Date
- ATOS 11-12-2024
- BWG 01-01-0001
- Dividend Yield
- ATOS N/A
- BWG 11.37%
- EPS Growth
- ATOS N/A
- BWG N/A
- EPS
- ATOS N/A
- BWG N/A
- Revenue
- ATOS N/A
- BWG N/A
- Revenue This Year
- ATOS N/A
- BWG N/A
- Revenue Next Year
- ATOS N/A
- BWG N/A
- P/E Ratio
- ATOS N/A
- BWG N/A
- Revenue Growth
- ATOS N/A
- BWG N/A
- 52 Week Low
- ATOS $0.62
- BWG $6.86
- 52 Week High
- ATOS $2.31
- BWG $8.65
- Technical
- Relative Strength Index (RSI)
- ATOS 54.46
- BWG 51.10
- Support Level
- ATOS $1.40
- BWG $8.74
- Resistance Level
- ATOS $1.58
- BWG $8.90
- Average True Range (ATR)
- ATOS 0.08
- BWG 0.06
- MACD
- ATOS -0.00
- BWG -0.01
- Stochastic Oscillator
- ATOS 52.17
- BWG 26.86
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About BWG BrandywineGLOBAL Global Income Opportunities Fund Inc.
BrandywineGLOBAL - Global Income Opportunities Fund Inc is a non-diversified, closed-end management investment company. The primary investment objective is to provide current income. The secondary investment objective is capital appreciation. The Fund seeks to achieve its investment objectives by investing, under normal market conditions, at least 80% of its assets in global fixed-income securities.